Analysts Are Bullish on These Healthcare Stocks: CG Oncology, Inc. (CGON), Qiagen (QGEN)

CG Oncology's Creto Launch Could See Headwind From Reimbursement Incentives, RBC Says

CG Oncology Is Maintained at Buy by Truist Securities

CG Oncology Is Maintained at Outperform by RBC Capital

RBC Raises Price Target on CG Oncology to $73 From $61, Keeps Outperform, Speculative Risk

CG Oncology price target raised to $73 from $61 at RBC Capital

CG Oncology Is Maintained at Overweight by Piper Sandler

CG Oncology price target raised to $70 from $55 at Piper Sandler

CG Oncology Expands At-The-Market Equity Offering Capacity

CG Oncology Inc Files for Offering of up to $550 Mln Common Stock - SEC Filing

CG Oncology Director James Mulay Reports Disposal of Common Shares

CG Oncology Is Maintained at Buy by Truist Securities

Wedbush Raises Price Target on CG Oncology to $77 From $70, Keeps Outperform Rating

Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology

CG Oncology price target raised to $66 from $62 at Truist

CG Oncology price target raised to $93 from $89 at Morgan Stanley

CG Oncology Up Over 27%, on Track for Record High Close and Record Percent Increase -- Data Talk

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January